Orforglipron vs Semaglutide | Research Comparison | QSC

Orforglipron vs Semaglutide: Research Comparison

Mechanism, clinical data, and research applications compared

Shop Both Compounds at QSC →

Factor Orforglipron Semaglutide
Drug Class Non-peptide GLP-1R agonist GLP-1R monoagonist (peptide, injectable)
Route Oral once-daily SC weekly / oral
Phase 2/3 Result −14.7% (36 wks)* −14.9% (68wks)
At QSC ✓ In Stock ✓ In Stock
Research Analysis: Orforglipron is oral non-peptide; semaglutide requires weekly injection. Comparable efficacy trajectories.
Research Use Only: All QSC products for in vitro laboratory research only. Not for human use.
Peptides
Orals
Oils
Search
Contact